May 18, 2020 / 6:15 AM / 19 days ago

BRIEF-Glaxosmithkline Says Study Shows Injectable Cab La 69% More Effective Than Daily Pills In Preventing HIV Acquisition

May 18 (Reuters) - GlaxoSmithKline PLC:

* GLAXOSMITHKLINE PLC - VIIV PREP JAB SHOWS HIGH EFFICACY OVER DAILY PILL

* GSK - ANALYSIS FROM STUDY SHOWS INVESTIGATIONAL, LONG-ACTING INJECTABLE CAB LA IS 69% MORE EFFECTIVE THAN DAILY PILLS IN PREVENTING HIV ACQUISITION

* GSK - STUDY ACHIEVED PRIMARY OBJECTIVE OF NON-INFERIORITY WITH DIFFERENCE APPROACHING SUPERIORITY IN FAVOUR OF CABOTEGRAVIR, PENDING FINAL ANALYSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below